In the News

Research led by Josie Robertson Investigator Karuna Ganesh provided clues that microbiomes might explain the increase in colorectal cancer among younger patients.

African American patients with colorectal cancer are less likely to have tumors that respond well to newer treatments such as targeted therapy and immunotherapy.

MSK’s Mobile Health Unit provides health education, screening, and navigation services to underserved communities in the New York metro area.

Cassidy Cobbs is many things: a valued colleague who works at the Sloan Kettering Institute; a doting parent to a pit bull named Mando; a beloved sibling; and a passionate baseball fan, who memorized the stats of former player, Ryne Sandberg, at the age of 5. What Cassidy is not is someone who identifies as either a man or a woman.

A team of scientists at the Sloan Kettering Institute has identified the STING cellular signaling pathway as a key player in keeping dormant cancer cells from progressing into aggressive tumors months, or even years, after they’ve escaped from a primary tumor.

New research published in The New England Journal of Medicine finds adding the immunotherapy drug pembrolizumab (Keytruda®) to standard chemotherapy greatly improves outcomes in people with advanced endometrial cancer. The phase 3 study was overseen by MSK gynecologic medical oncologist Carol Aghajanian.

New research from MSK offers new proof-of-concept compounds against acute myeloid leukemia; reports results from a phase 1 clinical trial appraising two drugs against low- grade glioma; examines MSK’s first-in-the-nation program integrating herbal medicine into oncology care; and identifies how high-grade histologic patterns in lymph node metastases could better predict lung cancer outcomes.

A groundbreaking clinical trial is testing CAR T cells created using CRISPR gene-editing technology.

Learn how MSK researchers are investigating the use of nanoparticles to carry drugs across the blood-brain barrier.

Memorial Sloan Kettering Cancer Center (MSK) is committed not only to providing exceptional cancer care but also to ensuring access to care for everyone who needs it. Unfortunately, some patients — often those whose insurance plan offers a very narrow provider network or those who are underinsured — have trouble shouldering the significant financial burden that can come with a cancer diagnosis. MSK has a special team in place to make sure these patients can still get the care they deserve.